Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIN-301
- Development stage
- Preclinical
- Lead developer
- Minerva Neurosciences
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous[2]
01
Overview
MIN-301 is a recombinant form of the neuregulin-1β1 protein, specifically comprising the extracellular domain of neuregulin-1β1. It is being developed as a neuroprotective and disease-modifying therapy for Parkinson's disease. Preclinical studies have shown that MIN-301 can restore motor function and improve cognition in animal models of Parkinson's disease by acting as an agonist at the ERBB 4 receptor. The drug aims to slow or reverse brain tissue damage associated with neurodegenerative disorders. Development has focused on Parkinson’s disease; previous development efforts for Alzheimer’s disease, schizophrenia, and other CNS disorders have been discontinued[1][2][4][5][6].
- Other names
- NRG 101NRG101NRG-101neuregulin-1β1 recombinant protein
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on MIN-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIN-301.